Prostate Cancer Trial Results
- Higher Radiation Dose Reduces "Biochemical Recurrence" of Prostate Cancer
(Posted: 10/03/2005, Updated: 03/15/2010) - Men with early-stage prostate cancer who received higher doses of radiation were less likely than men who received the conventional dose to have rising levels of prostate-specific antigen (PSA), a phenomenon referred to as “biochemical recurrence,” according to the March 1, 2010, issue of Journal of Clinical Oncology.
- Several Drugs Appear Effective for Hot Flashes in Men with Prostate Cancer
(Posted: 02/25/2010) - Clinical trial results published online December 4, 2009, in The Lancet, show that an antidepressant and two different hormone therapies reduced the number and intensity of hot flashes in men receiving hormonal treatment for advanced prostate cancer.
- Denosumab Keeps Bones Strong during Prostate Cancer Treatment
(Posted: 10/28/2009) - Treatment with the monoclonal antibody denosumab increased bone mineral density (BMD) and reduced the risk of fractures in men who received a common treatment for prostate cancer that had not spread to other parts of the body, according to the results of a large, placebo-controlled clinical trial published in the August 20, 2009, New England Journal of Medicine.
- U.S. Cancer Screening Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening
(Posted: 03/18/2009) - Six annual screenings for prostate cancer led to more diagnoses of the disease, but no fewer prostate cancer deaths, according to a major new report from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a 17-year project of the NCI. The PLCO was designed to provide answers about the effectiveness of prostate cancer screening.
- Radiation Plus Hormone Therapy for Locally Advanced Prostate Cancer Improves Survival
(Posted: 02/03/2009) - Clinical trial results published online December 15, 2009, in The Lancet, affirms earlier studies showing that adding radiation therapy to hormone therapy (HT) is more effective than HT alone for locally advanced prostate cancer.